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modestly with CRX2 at Bx1, but strongly at Bx2, particularlyPredictive power of the second renal biopsy in lupus nephritis:
IFI, BxInfl, and glomerular and tubular macrophages. StainsSignificance of macrophages.
for macrophage markers form a valuable adjunct in interpreta-Background. A new Biopsy Index containing the Glomeru-
tion of renal biopsies in systemic lupus erythematosus (SLE).lar Activity (GAI), Tubulointerstitial Activity (TIAI), Chronic
MPGN features do not have an ominous significance at Bx1,Lesion (CLI), and Immunofluorescence (IFI) indices was de-
but their persistence or appearance under therapy are associ-veloped, showing better correlations with clinical and outcome
ated with poor outcome.parameters than the National Institutes of Health Activity and
Chronicity Indices (AI and CI) in lupus nephritis. This report
examines the ability of these indices and individual morpho-
logic variables to predict doubling of serum creatinine (SCr; We have had the opportunity to study a series of 71CRX2).
patients with initial biopsies and systematic control biop-Methods. Renal biopsies from 71 patients with lupus nephri-
tis with an initial biopsy (Bx1) and systematic control biopsy sies at six months after the induction of therapy [1].
(Bx2) after six months of therapy were studied. Kaplan–Meier On the basis of this material, a new biopsy index was
survival curves were developed for each index and morphologic developed, composed of four elements: Glomerular Ac-
variable at each biopsy. A subset of 30 biopsies was stained
tivity Index (GAI), a modification of the standard NIHwith the macrophage marker PGM1.
Activity Index (AI) [2, 3] with the addition of glomerularResults. At Bx1, only the TIAI and the quantity of C3 and
vascular staining on IF were predictive of CRX2. At Bx2, monocytes and elimination of interstitial inflammation;
particularly predictive of CRX2 were the GAI, IFI, Biopsy Tubulointerstitial Activity Index (TIAI) analogous to
Index, and BxInfl, a composite variable comprised of all of the the GAI, evaluating several tubular epithelial and in-
inflammatory variables. Among individual variables, glomeru-
flammatory components, including interstitial inflam-lar and tubular macrophages correlated the best with clinical
mation, but excluding tubular atrophy; Chronic Lesionsand outcome parameters. Crescents and karyorrhexis/fibrinoid
necrosis also correlated with outcome. Neither the NIH CI or Index (CLI), a modification of the standard NIH CI
our CLI, nor the TIAI correlated with outcome. In 30 biopsies [2, 3], with the addition of glomerular scars; Immunoflu-
stained with PGM1, PGM11 cells correlated well with glomer- orescence Index (IFI), a semiquantitative index of immu-
ular and tubular macrophages identified on routine stains and
nofluorescence (IF) staining of glomerular capillary andshowed even better correlations with SCr, proteinuria, and pro-
mesangial, tubulointerstitial, and vascular elements bygression to renal insufficiency than the latter. A diffuse mem-
branoproliferative (MPGN) pattern was seen in seven patients six standard antisera. This new biopsy index and/or its
at Bx1. In four of the seven patients, MPGN disappeared with components showed better correlations with nearly all
therapy, and all finished with normal renal function. However, clinical and outcome parameters, including serum creati-
among the three patients in whom MPGN persisted and eight
nine (SCr), proteinuria, doubling of SCr (CRX2), end-patients in whom MPGN, focal or diffuse, appeared under
stage renal disease (ESRD), and final renal function thantherapy, six reached end-stage renal disease, and a seventh
died with marked renal insufficiency. the standard AI and CI [1].
Conclusions. The biopsy index and its components correlate The purpose of the present communication is three-
fold. The first is to evaluate the power of the biopsy index
and its component morphologic variables in predictingKey words: NIH Activity and Chronicity Indices, serum creatinine,
CRX2. There has been dissatisfaction with the presentlymembranoproliferative nephritis, chronic renal insufficiency, inflam-
mation. employed AI and CI in terms of their predictive power,
and Investigators seem to be in agreement that the AIReceived for publication March 14, 2000
seems to have little predictive power [4–9], at least atand in revised form June 29, 2000
Accepted for publication August 7, 2000 first biopsy. A number of investigators have found that
the CI was moderately predictive of renal survival [2, 3,Ó 2001 by the International Society of Nephrology
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7, 8, 10–14], although some have not [4, 6, 9, 15]. Other Technical methods and biopsy data
combinations of variables have been used in an attempt Specifics of technical methods are given in the prior
to improve the correlations between biopsy and outcome communication [1]. Briefly, light microscopic slides were
with some success [2, 11, 12], but none has been entirely prepared and stained according to standard methods for
satisfactory. Similarly, in our current study, at the time light and IF microscopy. For technical reasons, six cases
of the first biopsy very few variables were predictive of at Bx1 were unsatisfactory for detailed morphologic eval-
outcome, and none was predictive in a manner that could uation, although diagnosis of diffuse proliferative lupus
be applied to an individual case, because of the marked nephritis was established on the basis of paraffin-embed-
overlap between cases that did and did not progress to ded IF material. Photographs of positive IF were avail-
CRX2. However, at the time of the second biopsy, a able in 122 (85.9%) of the 142 first and second biopsies,
and the biopsy report systematically detailed all results.number of features were predictive of CRX2 in a fashion
In the remaining cases, photographs were not availablethat would permit the pathologist to indicate to the clini-
and/or the specimen consisted of medulla only.cian that the patient was at risk of progression to CRX2,
The following clinical parameters were evaluated atdespite a relatively quiescent clinical picture.
the time of each biopsy: systemic lupus erythematosusSecond, our previous communication revealed unex-
activity index (SLEDAI) [17], blood pressure, CH50,pectedly strong correlations between glomerular mono-
C3, C4, anti-DNA antibodies (DNA), SCr (mmol/L), pro-cytes and tubular macrophages on the one hand and
teinuria (g/24 h), and hematuria (rbcs/mL), hemoglobin,clinical and outcome parameters on the other [1]. To
and platelets. Clinical data were available for all patientsexplore these findings in more detail, we used immuno-
for the initial two biopsies, but for six patients, follow-histochemical staining of a subset of biopsies with the
up data as to outcome are incomplete.macrophage marker PGM1 (a monoclonal antibody spe-
Four overlapping outcome parameters were mea-cific for the CD68 cell surface antigen of macrophages).
sured: (1) doubling of the initial SCr (CRX2) for threeThird, the significance of the membranoproliferative
months or more; (2) end-stage renal disease (ESRD),variant of diffuse proliferative lupus nephritis, character-
requiring dialysis and/or transplant; (3) renal relapseized by the presence of capillary double contours, was
(Renrel), recrudescence of renal disease after an initialexplored since 19 of the 71 patients showed this pattern,
therapeutic response, as defined by a recent increase offocally or diffusely, at some point in their course.
SCr by .50% with active urinary sediment and/or in-
crease in proteinuria to 3.5 g/day or greater; and (4) final
METHODS renal function (RFlast), the last SCr, with an arbitrary value
of 500 mmol/L assigned to all patients with ESRD, onPatient population
dialysis or transplanted.
Renal biopsies and clinical data from 71 patients from
four Paris hospitals (Bichat, Broussais, Henri Mondor, Morphologic variables
and St. Louis) from the period 1986 to 1994 were evalu- The schema for evaluation of morphologic variables
ated. All patients had at least four ARA criteria, with has been reported in detail in our earlier communication
positive antinuclear and/or anti-DNA preparations in all. [1]. Briefly, the method of grading morphologic lesions
The patients had the following demographic distribution: parallels that used by Austin et al [2, 3], but adds consid-
There were 63 females and 8 males, with a mean age of eration of tubular lesions and IF data. As in their system,
36.8 6 13.8 years at first biopsy; ethnic origins were 40 the various morphologic lesions were graded on a scale
Caucasian, 13 North African, 10 Asiatic, and 8 black of 0 to 31, with 11 corresponding to involvement of
patients. Mean follow-up was 7.6 6 2.9 years (range of less than 25% of the glomeruli or parenchyma by the
0.7 to 13.4 years). All patients who had an initial renal variable in question; 21, 25 to 50%; and 31, greater
biopsy (Bx1), with systematic second biopsy (Bx2) at six than 50% of the glomeruli/parenchyma. We modified
months after induction treatment, were included. From this grading system slightly, giving a value of 0.51 to
the third biopsy onward, biopsies were performed pri- lesions that were present, but minimal, for example, less
marily for clinical indications and are not discussed in than 5% of glomeruli, in the hope of refining somewhat
detail here, but will be reported in a subsequent commu- the distinctions in the many instances in which lesions
nication. All biopsies were reviewed by one pathologist of a given type were not widespread. The GAI, CI, and
(G.S.H.) who was blind to the clinical data. Cases were TIAI were formulated using this approach.
categorized according to the 1982 World Health Organi- An IFI was devised in the following manner. Antisera
zation criteria [16]. No case of focal proliferative GN or to the following were employed in all cases: IgG, IgA,
of mixed membranous and focal proliferative GN was IgM, C3, C1q, and fibrinogen. Four separate morpho-
logic components were evaluated: glomerular capillarydiagnosed with fewer than 10 glomeruli.
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Table 1. Components of Biopsy Index be determined because of the plane of section, overlap
with other capillary loops, etc. We estimate this group toIndex name Symbol Scale
constitute roughly 30% of glomerular capillary deposits.Glomerular Activity Index (GAI)
Glomerular proliferation glprolif 0–31 Deposits in each category were graded semiquantita-
Polymorphonuclear leukocytes glpmn 0–31 tively on a scale of 0 to 41, relying primarily on the
Karyorrhexis/fibrinoid necrosis karyfib (0–31) X2
extent of deposits in the tuft.Cellular crescents cresc (0–31) X2
Hyaline deposits hyaldep 0–31 Arterial and arteriolar lesions were recorded but were
Glomerular monocytes glmono 0–31 not included in the Biopsy Index because their correla-
Maximum: 24
tions with clinical and outcome variables were relativelyTubulointerstitial Activity Index (TIAI)
Tubular cell pyknosis tubpyk 0–31 weak, and their inclusion in the biopsy index weakened
Tubular nuclear “activation” tubact 0–31 its correlations. In the present study, only vascular IF
Tubular cell necrosis tubnec 0–31
was included.Tubular cell flattening tubflat 0–31
Macrophages in tubular lumens macrlum 0–31
Epithelial cells in tubular lumens eplum 0–31 Immunohistochemistry
Interstitial inflammation intinfl 0–31
Immunostaining for the macrophage marker PGM1Maximum: 21
Chronic Lesions Index (CLI) (Dakopatts, Trappes, France) was performed on a subset
Glomerulosclerosis glscl 0–31 of 30 biopsies from the overall series, 14 from Bx1, and
Glomerular scars gloscar 0–31
16 from Bx2, as follows: Freshly cut paraffin slides wereFibrous crescents fibcres 0–31
Tubular atrophy tubatro 0–31 digested with pronase, followed by blocking with goat
Interstitial fibrosis intfib 0–31 serum diluted 1/20 for 20 minutes. They were then incu-
Maximum: 15
bated 30 minutes with PGM1, washed with Tris buffer,Immunofluorescence Index (IFI)
Glomerular capillary IF glcapif (0–41) X6 antisera pH 7.4, followed by 30 minutes of incubation with horse
Glomerular mesangial IF glmesif (0–41) X6 antisera anti-mouse antibody to detect the PGM1, washed, and
Tubulointerstitial IF tubulif (0–41) X6 antisera
then incubated with a preformed avidin-biotinylated al-Vascular IF vascif (0–41) X6 antisera
Maximum: 96 kaline phosphatase complex. Development with vector
red AEC (3-amino-9-ethylcarbazol) substrate and coun-
Biopsy Index 5
GAI
8
1
CI
5
1
TIAI
7
1
IF Index
32
5 Maximum 12.
terstaining with hematoxylin completed the process.
Macrophage cell counts
Slides were examined using an ocular grid subdividedIF (glcapif), glomerular mesangial IF (glmesif), vascular
into 100 squares, yielding an overall area of approxi-
IF (vascif), and tubulointerstitial IF (tubulif). The degree
mately 10,000 m2 at 340 magnification. Only the cortical
of staining for each antiserum was graded on a scale of
parenchyma was evaluated. For each biopsy, all glomer-
0 to 41 for each component, and the totals for all the uli were evaluated, plus the equivalent of at least 100
antisera were then added for a maximum of 24 for each grids of tubulointerstitium, with the exception of two
component. In addition to the IFI, total staining for each biopsies in which only 72 and 80 grids could be counted
antiserum was calculated (maximum for 16 per antise- because of limited material. The following morphologic
rum). The overall biopsy index, with the abbreviations compartments were evaluated: (1) glomerular capillary
used in this article, is shown in Table 1. lumenal macrophages, (2) glomerular macrophages not
In addition, for this study, glomerular capillary depos- within capillaries, (3) macrophages outside the glomeru-
its were divided by location on photographs of the IF. lar tuft in Bowman’s space, (4) tubular lumenal macro-
Three sorts of deposits were distinguished: The first were phages, (5) cells staining positively for PGM1 within the
definite subendothelial deposits, recognizable by smooth tubular epithelium, and (6) interstitial macrophages.
outer contour, corresponding to the glomerular base-
ment membrane and often encroaching on the capillary Statistical analyses
lumen. These were often fairly long, but occasionally For continuous clinical variables (for example, SCr),
short and somewhat comma shaped. The second were Pearson product-moment correlation coefficients were
definite subepithelial deposits, discontinuous and granu- calculated. The various morphologic indices, with maxi-
lar in nature, on the external aspect of the basement mal values ranging from 15 to 96, were treated as continu-
membrane (large transmural deposits were sometimes ous variables. In comparing semiquantitative variables,
recognized, and were included in the estimation of both such as hyaline deposits graded 0 to 31, with continuous
subendothelial and subepithelial deposits), and third variables Pearson product-moment correlations were
were deposits of indefinite location. These were usually used. For comparisons of semiquantitative variables with
small and/or pale, but occasionally deposits were in- one another, Spearman rank order correlations were
used. For categorical variables (for example, presence orcluded in this category because their location could not
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absence of ESRD), the Spearman rank order correlation treated with cyclophosphamide plus steroids and those
treated by steroids alone.test was used. Since these correlations are very exten-
Eighteen patients eventually doubled their SCr (CRX2),sively cited, to maintain continuity in the text, they usu-
all of whom had diffuse proliferative (WHO Class IV)ally appear simply in parentheses, and asterisks are used
lupus nephritis at initial biopsy. None reached CRX2 dur-to indicate the level of probability: *P , 0.05, **P ,
ing the initial six months of treatment. A point to be0.01, ***P , 0.001, and ****P , 0.0001. Thus, r 5 0.42,
stressed, there were no significant differences in any ofP 5 0.0006 would appear as (****0.42). Comparisons of
the laboratory parameters at Bx2 between those who latersurvival were done by the Kaplan–Meier method, with
progressed to CRX2 and those who did not. Differencesdifferences in survival curves evaluated by log rank sum
in degree of hematuria approached significance (37 6 63testing. Survival curves were calculated from the time
vs. 14 6 33 k rbc/mL, P 5 0.068), but the wide range ofof the first biopsy. Calculations were performed using
values rendered this useless in distinguishing between theStatisticat Version 5 (Statsoft, Inc., Tulsa, OK, USA).
groups. Twelve patients ended in ESRD, with dialysis
and/or transplantation, and five patients died, of whom
RESULTS three had arrived at CRX2. All patients with focal prolifer-
ative lesions finished with SCr at or near normal. OnePatient material and initial treatment
patient with mixed membranous and proliferative lesionsInitial diagnoses in this series were diffuse prolifera-
died rapidly of septicemia with SCr 5 350 mmol/L (buttive (WHO Class IV) lupus nephritis, 55 patients; focal
before technically having doubled her creatinine for theproliferative (WHO Class III) lupus nephritis, 9 patients;
requisite 3 months). The other patients with this lesionand mixed membranous and focal proliferative (1982
finished with normal function or mild renal insufficiency.WHO Class Vc) lupus nephritis, 7 patients. Fifty-eight
of the 71 patients had newly diagnosed renal involve- Overall morphologic changes between biopsy 1 and
ment; 13 patients had previously been treated for renal biopsy 2
involvement with a variety of regimens. These latter pa-
The alterations in the various morphologic parameterstients did not differ from other patients in level of morpho-
between Bx1 and Bx2 will be dealt with extensively in alogic lesions or clinical data at the time of entry to this
future communication (manuscript in preparation), butstudy. As might be anticipated, these patients tended to
certain generalizations must be made in order to put the
do somewhat worse as a group than the other patients,
present survival data into context. Taken globally, the
with a rate of CRX2 of 46.1 versus 23.1% for the re-
data provide evidence that the most immediate effect of
maining patients, but this difference did not reach the therapy is reduction of the inflammatory components,
level of significance (P 5 0.10). In addition, 15 patients such as crescents and interstitial inflammation, with lesser
had been previously treated for extrarenal manifestations, reductions in the amount of immune deposits by IF. The
generally with low dose steroids and/or chloroquine. second generalization that can be made is that, although
They even more nearly approached the remaining pa- initial levels were similar in the two groups, reductions
tients in terms of morphologic lesions, clinical data, and between biopsies were invariably less in the group subse-
rates of CRX2 (33.3 vs. 26%, P 5 0.57). quently developing CRX2 (CRX2 5 1). As an example,
The six-month induction treatment consisted of values for the GAI for the group not doubling their SCr
monthly intravenous cyclophosphamide combined with (CRX2 5 0) are 10.4 6 4.9 declining to 2.9 6 2.9 at Bx2.
prednisone (0.9 6 0.4 mg/kg body weight/day for one For the CRX2 5 1 group, the GAI began at comparable
month tapered to 0.4 6 0.1 mg/kg body weight/day at 6 levels, 11.2 6 4.9 but declined only to 6.1 6 4.7 at Bx2.
months) in 58 patients and corticosteroids alone in 13 Thus, although there is no difference between initial val-
patients (1.4 6 0.3 mg/kg body weight/day tapered to ues in the two groups, the difference between the two at
0.5 6 0.16 mg/kg body weight/day at 6 months). Initial Bx2 is substantial (P 5 0.0021).
treatment was followed at six months by re-evaluation Taking these processes collectively and indexing initial
and control renal biopsy to evaluate the effects of therapy. values for the CRX2 5 0 group to 1 at Bx1 to facilitate
Therapy was adjusted at this point by the clinician in the comparison, overall immune deposits by IF declined from
light of the clinical setting and biopsy findings. (In general, 1.0 to 0.5426 in the CRX2 5 0 group. In the CRX2 group,
in the face of biopsies showing continuing activity, treat- they started slightly (but not significantly) higher, 1.1131
ment was more aggressive than in patients with more but descended only to 0.8622 for CRX2 5 1, the difference
quiescent biopsies, but treatment was not completely stan- between the two groups at Bx2 being highly significant
dardized, and evaluation of that treatment is outside the (P 5 0.0035). Similarly, BxInfl, a composite variable com-
scope of this article.) Subsequent biopsies were carried posed of all of the inflammatory morphologic variables,
out primarily for clinical indications. There was no differ- declined from 1.0 to 0.2176 for CRX 5 0; comparative
values for the CRX2 5 1 group being 1.2222 descendingence in clinical data at entry or in outcome between those
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to 0.6384 for CRX2 5 1 (P , 0.00005). There were fluctu- vascular IF showed significant predictive value, but glo-
merular mesangial IF did not.ations among individual inflammatory variables and in
immune deposits according to whether they were consid-
Monocytes and macrophagesered by location (for example, subendothelial, tubuloin-
Glomerular monocytes and tubular macrophages areterstitial) or by antiserum type (for example, anti-IgG),
worthy of separate comment. At Bx1, glomerular macro-but all followed these general trends. By contrast, tubular
phages were the most sensitive among the glomerularepithelial alterations and chronic lesions such as interstitial
variables [glomerular proliferation, polymorphonuclearfibrosis rose (chronic lesions) or fell (tubular epithelial
cells (PMNs), karyorrhexis, crescents, hyaline deposits, andlesions) in parallel in the two groups, the differences not
macrophages] in distinguishing among clinical parameters.reaching statistical significance.
Evaluating the correlations of these variables with CH50,
Prediction of outcome DNA, SCr, proteinuria, hematuria, and hemoglobin (Hgb),
glomerular macrophages had the highest mean coeffi-The predictive power of each of the morphologic vari-
cient of determination (r2) at 0.0825 6 0.0529. The otherables and morphologic indices in terms of survival from
glomerular variables had r2s ranging between 0.0177 6developing CRX2 up to 10 years was evaluated at both
0.0295 (P , 0.00001) and 0.0588 6 0.0636 (P 5 0.028).Bx1 and Bx2 by standard Kaplan–Meier survival curves,
At Bx2, differences in clinical parameters were muchwith the significance of differences between curves deter-
more muted because of the decline in overall morpho-mined by log rank sum testing. All patients were consid-
logic activity. However, now the simple presence or ab-ered in these calculations (although, in fact, in this series,
sence of glomerular monocytes became a significantonly those with diffuse proliferative lesions reached CRX2).
prognostic factor for CRX2 (Table 2).At Bx1, neither the standard AI and CI nor the overall
Similarly, tubular lumenal macrophages (macrlum)biopsy index was predictive of progression to CRX2, al-
were the most powerful of any of the variables constitutingthough the TIAI taken alone was weakly predictive (Table
the TIAI. The patients with macrlum $1 (13 patients) at2). The only individual morphologic variables reaching
Bx1 were manifestly sicker than those with macrlum 5 0statistical significance were C3 on IF and vascular IF.
(40 patients). They had a higher frequency of hyperten-At the second biopsy, the biopsy index and two of
sion (P 5 0.022). DNAs were higher (P 5 0.006), andits component indices, GAI and IFI (Fig. 1A), showed
the SCr was nearly double that in patients without lumenalsignificant differences in survival from CRX2 divided sim-
macrophages (190 6 107 vs. 106 6 53, P 5 0.0005). Atply above and below their means, with greater differences
Bx2, the disparity in those with (14 patients) and those
in survival with selection of values further from the mean.
without (56 patients) tubular macrophages was similar,
At Bx2, the standard AI showed significant differences with higher DNAs (P 5 0.039) and higher SCr (P 5 0.0005).divided above and below the mean, with greater differ- More importantly, as indicated previously in this article,
ences with selection of appropriate values. In contrast, the simple presence or absence of macrophages in the
neither the standard CI nor our revised CLI nor the TIAI tubular lumens was the single best individual morphologic
served to separate survivals from CRX2 adequately. Of variable determining survival in terms of CRX2 (Table 2).
the composite variables comprised of multiple individ- Overall, among the tubular morphologic variables, tubular
ual variables, BxInfl, composed of all of the inflamma- lumenal macrophages had the highest correlation with
tory morphologic variables (glpmn 1 glmono 1 cresc 1 clinical parameters at Bx1 and the highest correlation with
karyfib 1 intinfl 1 pmnlum 1 macrlum), showed the outcome parameters at Bx2 and the best combination
greatest ultimate separation between cases. The mean of clinical and outcome correlations for the two biopsies
value was 1.73, dividing cases into 83.5 versus 22.3% considered together (data not shown).
survivals at 10 years (P 5 0.00006; Fig. 1B). However,
selecting cases with values ,1.0 and .4.0 provided Immunohistochemical studies
CRX2 survivals of 94.4% at 4500 days versus 0% at 1707 Macrophage staining for PGM1 revealed excellent cor-
days onward (P 5 0.00005; Fig. 2). relations with the simple variables glomerular monocytes
At the second biopsy, the simple presence or absence and tubular lumenal macrophages in the biopsy index
of karyorrhexis/fibrinoid necrosis, cellular crescents, glo- (Table 3). These variables had been evaluated semiquanti-
merular monocytes, and tubular macrophages had signifi- tatively 0 to 31 on the basis of the percentage of glomeruli
cant predictive power for CRX2. The strongest of these with recognizable monocytes in excess of one and the
individual morphologic variables was tubular lumenal percentage of tubular profiles containing recognizable
macrophages, with CRX2 survivals at 10 years of 73.9% macrophages on routine stains. First, glomerular mono-
for those without tubular macrophages versus 18.2% for cytes identified on routine stains correlated well with their
those with (P 5 0.0072; Fig. 3). Among the components closest counterpart, glomerular capillary PGM11 cells
(**0.54), and similarly, tubular lumenal macrophagesof the IFI, glomerular capillary, tubulointerstitial, and
Table 2. Survivals at 3200 days from CRX2 for various indices and morphologic variables
N Proportion N Proportion
Score patients surviving Score patients surviving P
Morphologic Indicesa
Biopsy 1
Glomerular Activity Index 1 #10 27 0.6566 .10 31 0.7645 NS
Chronicity Index 1 #2.5 36 0.7979 .2.5 21 0.5247 NS
#1 19 0.7782 .4 13 0.5128 NS
Tubulointerstitial Activity Index 1 #5 28 0.7863 $8 14 0.4614 0.046
Immunofluorescence Index 1 #26 25 0.7196 .26 24 0.6539 NS
Biopsy Inflammation 1a #5.5 32 0.7542 .5.5 26 0.6335 NS
Biopsy Index 1 #4.2 27 0.7744 .4.2 17 0.5156 0.078
Biopsy 2
Glomerular Activity Index 2 #3.5 390 0.7940 .3.5 24 0.4850 0.016
,3 31 0.8104 .8 8 0.0000 0.0007
Chronicity Index #3.8 33 0.7425 .3.8 30 0.6058 NS
Tubulointerstitial Activity Index 2 #3 22 0.7377 .7 14 0.4726 0.055
Immunofluorescence Index 2 #16 27 0.8366 .16 22 0.4054 0.005
#9 13 0.9231 .24 13 0.3042 0.005
Biopsy Inflammationa #1.7 38 0.8681 .1.7 22 0.3349 0.00004
,1 21 0.9444 $4 9 0.0000 0.00005
Biopsy Index 2 #2.9 26 0.8106 .2.9 21 0.4381 0.006
#2 14 0.8750 .4 12 0.2922 0.002
Individual morphologic variables
Biopsy 1
Karyorrhexis/fibrinoid necrosis 0 13 0.5858 .0 45 0.7541 NS
PMNs in glomerular capillaries 0 26 0.7342 .0 32 0.6858 NS
Cellular crescents 1 0 25 0.6866 .0 33 0.7131 NS
Glomerular monocytes 1 0 13 0.7252 .0 45 0.6995 NS
Membranoproliferative features 0 39 0.6712 21 7 0.8571 NS
Tubular macrophages 1 0 36 0.7623 .0 24 0.5875 NS
Glomerular capillary IF 1 #11 27 0.6881 .11 23 0.7158 NS
Glomerular mesangial IF 1 #8 26 0.7673 .8 24 0.6265 NS
Tubulointerstitial IF 1 #3 28 0.6976 .3 21 0.6793 NS
Vascular IF 1 #3 29 0.8273 .3 21 0.4987 0.03
IF-IgG 1 #6 25 0.7112 .6 24 0.6204 NS
IF-C3 #4 15 0.8750 .6 9 0.3703 0.009
Biopsy 2
Karyorrhexis/fibrinoid necrosis 2 0 40 0.6851 .0 10 0.2667 0.01
PMNs in glomerular capillaries 0 42 0.6608 .0 8 0.3333 0.13
Cellular crescents 2 0 41 0.6526 .0 9 0.3333 0.01
Glomerular monocytes 2 0 40 0.6759 .0 11 0.3535 0.03
Membranoproliferative features 0 53 0.7084 .0 9 0.4000 0.22
Tubular macrophages 2 0 38 0.7388 .0 12 0.1820 0.007
Glomerular capillary IF 2 #6.5 25 0.7804 .6.5 24 0.4831 0.08
,4 10 0.7714 .10 10 0.0000 0.007
Subendothelial deposits-2 IF ,1.5 27 0.6637 .1.5 25 0.6143 0.37
#.b 23 0.8188 #,b 7 0.3333 0.03
Subepithelial deposits-2 IF ,1 36 0.6702 .1 16 0.5540 0.65
Glomerular mesangial IF 2 #4 27 0.7787 .4 22 0.4889 0.05
Total glomerular IF ,10.5 25 0.8177 .10.5 24 0.4570 0.02
Tubulointerstial IF 2 #2.5 29 0.8069 .2.5 20 0.3952 0.01
0 17 0.7894 .4 7 0.0000 0.01
Vascular IF 2 #3 26 0.7740 .32 23 0.4785 0.04
#1 14 0.6857 .5 7 0.2571 0.03
IF-IgG 2 ,5 27 0.8503 $5 22 0.3630 0.009
IF-IgA2 ,1.5 23 0.7446 .1.5 25 0.5459 0.20
IF-IgM2 ,1.5 29 0.7140 .1.5 19 0.5342 0.27
IF-total immunoglobulins ,8 29 0.8046 .8 19 0.3762 0.008
IF-C3 2 $3 16 0.9375 .3 22 0.2759 0.0007
#2 19 1.000 .5 12 0.2500 0.00005
IF-C1q2 ,4 24 0.8890 .4 25 0.4124 0.0008
Standard indices
Biopsy 1
Activity Index 1 #10 16 0.5113 .10 29 .6813 NS
Chronicity Index 1 #2 28 0.7134 .2 17 .4867 NS
Biopsy 2
Activity Index 2 #4 29 0.7375 .4 22 0.4156 0.03
#1 12 0.6268 .6 15 0.2291 0.049
Chronicity Index 2 #2.5 24 0.6724 .2.5 27 0.5507 NS
Kaplan-Meier estimates of survival from CRX2, with the significance (P) of survival differences tested by the log rank test. Where more than one set of values
is indicated for a given morphologic index or parameter, the first set of values represents those above and below the mean value, and subsequent sets represent
values further removed from the mean. Most individual parameters are divided into 0 and .0, but immunofluorescence scores are cited in terms of the mean value
for that parameter. Values with log rank probabilities ,0.05 are indicated in boldface.
a Biopsy inflammation 5 glmono 1 macrlum 1 glpmn 1 pmnlum 1 cresc 1 karyfib 1 intinfl
b Percentage reduction between Bx1 and Bx2
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Fig. 1. (A) Immunofluorescence index (IFI):
Survival from doubling of serum creatinine
(SCr; CRX2). Results are from biopsy 2. Sur-
vival for patients above and below the mean
value for IFI 5 16. Survivals for patients with
IFI . 16 are indicated by a solid line; those
with IFI , 16 by a dotted line. Log rank test:
P 5 0.01415. (B) Biopsy inflammation, and
survival from CRX2. Results are from biopsy
2. Survivals for patients above and below the
mean value for BxInfl 5 1.73. Survivals for
patients with BxInfl . 1.73 are indicated by
a solid line, and those with BxInfl #1.73 by a
dotted line. Log rank test, P 5 0.00006. The
separation between survival curves is greater
for BxInfl than for IFI and the probabilities
are correspondingly different.
Fig. 2. Biopsy inflammation: Survival from
CRX2. Survival curve for Bxinfl ,1 is indi-
cated by a thick solid line, and that for
BxInfl . 4 by a thinner solid line. Arrow indi-
cates a censored case who died with SCr 5 350
mmol/L, but before qualifying as CRX2.
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Fig. 3. Tubular lumenal macrophages: Sur-
vival from CRX2. Results are from biopsy
2. Survival curve for cases with no tubular
lumenal macrophages is indicated by a dotted
line, and that for cases with tubular macro-
phages by a solid line. Log rank test, P 5
0.0072.
Table 3. Comparison of glomerular and tubular lumenal
macrophages (archival material) with immunohistochemical
macrophage marker PGM1 in 30 Biopsies
Glomerular Tubular lumenal
macrophages macrophages
PGM11 macrophages r P r P
Glomerular
Capillary 0.5355a 0.002a 0.2498 NS
Noncapillary/mesangial 0.3955a 0.031a 0.1497 NS
Total glomerular 0.5555a 0.001a 0.1200 NS
Bowman’s space 0.2250 NS 0.5482a 0.002a
Tubular
Tubular lumenal 0.3361 0.069 0.5246a 0.003a
Epithelial 0.2709 NS 0.5505a 0.002a
Total tubular 0.3285 0.076 0.5740a 0.001a
a Significant at P , 0.05
Fig. 4. Glomerular macrophages, PGM1 antiserum: Glomeruli show-correlated well with their PGM11 counterparts (**0.52).
ing lumenal (arrowhead) and mesangial (thin arrow) macrophages. In
In addition, there were excellent correlations with non- addition, a nearby tubule shows basolateral staining of two epithelial
cells (thick arrow; 3300).capillary glomerular PGM11 cells. These latter were of-
ten clearly mesangial in location in milder cases (Fig. 4),
but with more severe proliferation, their exact location
became uninterpretable.
Similarly, there were good correlations between tubu-
lar lumenal macrophages and PGM11 staining in a tubu-
lar epithelial location (Fig. 5). The pattern of cytoplasmic
staining of these latter cells suggests that the positivity
arose because of transformation of existing epithelial
cells rather than infiltration by preexisting macrophages.
It was seen first in a basal position in cells with columnar
appearance and nuclei identical to those of adjacent epi-
thelial cells and gradually expanded to supranuclear re-
gions in a cell less typically epithelial. It only infrequently
appeared in discrete cells with rounded contours such
as one might see in the tubulitis of allograft rejection.
This is not an issue than can be resolved in the present
Fig. 5. Tubular macrophages, PGM1 antiserum: In addition to red-study because the necessary double marker studies nec-
staining macrophages free in the tubular lumens, several tubular epithe-
essary for confirmation were not performed. (However, lial cells (arrowheads) show positivity for PGM1, predominantly in a
basal position (3300).in another study on focal segmental glomerulosclerosis,
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Table 4. Correlations between macrophages and serum creatinine (SCr), proteinuria and renal insufficiency in 30 biopsies stained with PGM1
Renal insufficiencyb
SCr Proteinuria (16 biopsies at Bx2)
PGM11 macrophages r P r P r P
Glomerular
Capillary 0.4856a 0.007a 0.6471a 0.000 0.6422 0.0073
Noncapillary/mesangial 0.2109 NS 0.3273 0.077 0.8342 0.00006
Total flocculus 0.2161 NS 0.4174a 0.022 0.7516 0.00079
Bowman’s space 0.5756a 0.001 0.2924 NS 0.6158 0.011
Tubular
Lumenal 0.5485a 0.002a 0.4994 0.004 0.5605 0.024
Epithelial 0.7385a 0.000 0.3259 0.079 0.4761 0.062
Total tubular 0.6770a 0.000a 0.4509 0.012 0.5325 0.034
Interstitial 0.3412 0.065 0.2555 NS 0.4480 0.082
For comparison:
Glomerular monocytesc 0.3039a 0.000a 0.4927 0.000 0.3485 0.0048
Tubular lumenal macrophagesc 0.5089a 0.000a 0.2636 0.002 0.4408 0.0003
a Results significant at P , 0.05
b Renal insufficiency is defined here as SCr . 300 mmol/L
c These results were obtained from observations on routine stains of archival material and include all of the cases in the study at Bx1 and Bx2; in the instance of
CRX2 only the results at Bx2 are evaluated.
Table 5. Membranoproliferative lesions in diffuse proliferativesuch doubly positive tubular epithelial cells were identi-
lupus nephritis
fied. In that situation they were infrequent, much less
Biopsy 1numerous than tubular macrophages.) Finally, there was
Other diffusea strong correlation between the PGM11 cells in Bow-
MPGN (21) proliferative Pman’s space and tubular lumenal macrophages.
N 7 patients 42 patientsBefore the beginning of treatment, at Bx1, there were
Hypertensive (%) 71.4% 23.8% 0.0059strong negative correlations between PGM11 glomerular
C3 3866177 5396182 0.0443
capillary macrophages and IgG (20.73***), C3 (20.71**), DNA 4006419 74261367 NS
Serum creatinine 2126134 121655 0.0035and C1q (20.64*). Similar but weaker correlations ex-
Proteinuria 5.964.8 5.164.3 NSisted for overall glomerular macrophages. However, after
Hematuria 42 K639 K 191 K6327 K NS
six months of treatment, at Bx2, these negative correla-
Biopsy 2 and subsequent biopiestions were effaced. The correlations were mildly positive,
MPGN persists or No MPGN orwith IgG (r 5 0.0087), C3 (r 5 0.3046), C1q (r 5 0.2070),
developsa MPGN disappears Pbut none were significant.
N 10 patients 39 patientsOn the clinical level, there were very strong correla-
ESRD 0.6000 0.1842 0.0069tions between glomerular PGM11 cells and proteinuria CRX2 0.6000 0.2821 0.0627
on the one hand and tubular PGM11 cells and SCr on RFlast 3356212 1936170 0.0257
the other (Table 4). These results are parallel to, but a Not included is an additional patient with mixed membranous and prolifera-
tive lesions, with MPGN at Bx2, who died shortly after, with SCr 5 350 mmol/L,perhaps somewhat better than, the correlations of pro-
but before technically qualifying as CRX2
teinuria and SCr and glomerular monocytes and tubular
macrophages from archival material indicated at the bot-
tom of Table 4. Similarly, correlations at Bx2 between case fairly closely resembled that of MPGN of other
causes.PGM11 cells and evolution to renal insufficiency (RI)
were excellent, both between glomerular PGM11 cells Those with full-fledged (21) MPGN (7 cases) were
more likely to be hypertensive at presentation and hadand RI (0.75***) and between tubular PGM11 cells and
RI (0.53*). The correlations with RI were, in fact, better much higher SCr (212 6 134 vs. 121 6 55, P 5 0.0035)
and lower C3 (Table 5). Clinically, they did not differthan those for glomerular and tubular macrophages for
the overall series, and in the instance of glomerular significantly in any other respect, including proteinuria
and hematuria. However, they responded well to therapy,PGM11 cells, this was significant.
and at Bx2, their SCr did not differ significantly from those
Membranoproliferative features without MPGN. Those in whom the MPGN features
disappeared had an excellent outcome, with no CRX2,Cases of membranoproliferative (MPGN) disease
were separated from those with other forms of diffuse and final renal function of 93 6 28. In contrast, among
three patients in whom MPGN features, even focal, per-proliferative disease. They were graded 11 if there were
only occasional double contours in a focal distribution sisted and seven patients in whom MPGN features ap-
peared under therapy (10 patients total), six reachedand 21 if these double contours were diffuse, and the
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ESRD (Table 5). In addition, a patient with mixed mem- dictive at Bx1, and the Biopsy Index marginally so, but
at Bx2, the GAI, IFI, and Biopsy Index were stronglybranous and proliferative lesions who developed MPGN
features at the second biopsy died with marked renal predictive of CRX2. The standard NIH AI at Bx2 was
also predictive of CRX2, but neither the standard NIHinsufficiency (SCr 5 350 mmol/L).
CI nor our revised CLI were predictive.
DISCUSSION Predictive ability of individual morphologic variables
Predictive ability of indices Among the individual morphologic variables, the one
that has consistently shown the best correlations withThe predictive ability of the AI and CI has been a
subject of debate over the years. By way of prologue, it outcome in the literature is subendothelial deposits [19,
25–28]. This is particularly true when they persist atshould be remembered that no two series are ever directly
comparable with one another, differing greatly in demo- second biopsy [19, 25]. Esdaile et al also found that while
subendothelial and mesangial deposits at Bx1 were notgraphic factors such as sex and race, duration of disease
prior to treatment, severity of clinical manifestations at predictive of outcome, the persistence of subendothelial
and mesangial deposits at Bx2 was associated with apresentation, and treatment. As an example, the largest
and best-studied group of patients currently extant is poorer survival [19]. Our experience parallels theirs in
that these variables were not predictive at Bx1, but glo-that of Austin et al with 166 patients followed prospec-
tively [11]. It contains 29.5% blacks, compared with our merular capillary IF, largely reflecting subendothelial
deposits, was significant at Bx2 (P 5 0.03), as were mes-series having 11.3% blacks. Although survivals from
CRX2 for blacks were the same in the two series (0.50 angial deposits (P 5 0.05). A direct estimate of subendo-
thelial deposits on IF confirmed that failure to resolvevs. 0.59), their effect on overall survival is obviously vastly
different. It is not surprising, then, that pathologists subendothelial deposits between Bx1 and Bx2 was also
associated with a poorer survival.working with the same morphologic tools should arrive
at different conclusions in different series. Even more strongly predictive in our series, however,
was the persistence of tubulointerstitial deposits on IF,With this in mind, some groups have found the AI to
be a significant predictor of renal outcome [2, 3, 7, 8, 10, although at Bx1 they had no predictive power (Table
2). Magil et al found tubulointerstitial deposits to be11, 15, 18]. However, Esdaile et al found that while the
AI and heavy subendothelial deposits were significantly significant [27], but in a later article on the same group
of patients with more extended follow-up [15], they werecorrelated with renal failure, they did not add significant
predictive value to their clinical model [12, 19]. Others of only marginal significance. As others have found [16],
vascular IF was a predictor of CRX2 at both biopsies.have been even less optimistic about the AI’s predictive
value, finding no significant correlation between the AI Overall though, the IFI at Bx2 was more strongly pre-
dictive of CRX2 (P 5 0.0026) than any of its individualand the outcome [4, 6, 8, 9, 20, 21]. In our own series,
neither the standard AI nor the GAI had a significant elements.
Cellular crescents at Bx1 have been found to be pre-predictive power at Bx1, but both were predictive at
Bx2, although not as strongly as the IFI (Table 2). dictive in some series [2, 10]. In our series, they were not
predictive at Bx1 but were moderately predictive at Bx2.The CI, or a variant thereof, has been found to be
predictive of outcome by some groups [8, 10, 11, 13, 14, Karyorrhexis with fibrinoid necroses has been found sig-
nificant by several groups [10, 15, 29], but in our material,18, 22]. In 1984, Austin et al found the CI to be a strong
predictor [3], but in subsequent publications proposed although predictive at Bx2, they were not predictive at
Bx1. Glomerulosclerosis has also been found to havethe alternative combinations of cellular crescents plus
interstitial fibrosis [2] and later, high-risk histology [11], predictive power by some groups [11, 15, 23, 27, 29]
but did not reach statistical significance in our seriesboth of which had greater predictive power than the CI.
Esdaile et al found that the CI was significant but did (discussed later in this article).
Among the tubulointerstitial variables previously de-not add predictive power to their clinical model [12, 23],
and later proposed their tubulointerstitial index [24], scribed as having prognostic significance at the Bx1 have
been tubular atrophy [2, 3, 11, 30], interstitial fibrosiswhich also had greater predictive power than the CI.
Finally, some groups have found the CI to have weak [2, 11], and interstitial inflammation [2, 8, 10, 30, 31]. In
our material, these measures, as well as the overall CI,or no correlations with outcome [4, 6, 9, 15, 20, 21]. In
our own case, the Bx1 or Bx2 material was not significant all tended to be worse in those destined to CRX2 at both
Bx1 and Bx2, but did not reach significance. However, inusing either the standard or the revised CI. In contrast,
the biopsy index, although only marginally significant at this study interstitial inflammation was found to be a
pivotal variable, strongly influencing the index into whichBx1 (P 5 0.078), was a strong predictor of CRX2 (and
ESRD, data not shown) at Bx2. it was incorporated. The variable, BxInfl, which includes
interstitial inflammation, was the most discriminatory ofIn summary, in this series, only the TIAI was pre-
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all the variables or indices at Bx2 in separating those gression of renal disease [19, 35, 41]. However, Oda et
later doubling their SCr from those not doubling it. al have recently studied in detail tubular lumenal cells
that they refer to as “giant” intratubular macrophages,
Monocytes and macrophages which appear from their descriptions and photos to rep-
The role of monocytes and macrophages in the pathol- resent the same cells we are describing [44]. In a variety
ogy of lupus nephritis has been underappreciated. In of glomerular conditions (not including SLE), they found
this study, glomerular monocytes and tubular lumenal that these macrophages correlated well with the SCr (r 5
macrophages were the individual variables that corre- 0.63), hematuria, and in the instance of IgA nephropathy,
lated best with clinical and outcome parameters. Glo- with proteinuria, basically results paralleling those in this
merular monocytes/macrophages have previously been study. To our knowledge, we are the first to describe the
found to be present in high numbers in SLE [15, 32–34] connection between tubular macrophages and clinical
and in our series showed the highest correlation with and outcome parameters in SLE, their association with
proteinuria (0.39**) of any morphologic variable at Bx1. CRX2 and with ESRD (data not shown) being particu-
A strong correlation between glomerular macrophages larly striking.
and proteinuria has been described in an older study The origin of the macrophages in tubular lumens is
[33] as well as experimentally [35]. Parallel with these not entirely certain. In other disease conditions, notably
observations, urinary levels of monocyte chemotactic focal segmental glomerulosclerosis [46] and nephrangi-
and activating factor, responsible for mediating glomeru- osclerosis [47], many of the tubular macrophages have
lar macrophage infiltration [36–38], have been found to been demonstrated to be of glomerular origin, owing to
reflect disease activity in lupus nephritis [39]. transdifferentiation of podocytes. It seems likely that this
Although the presence of monocytes on urine cytology is the case here as well, for there is a strong correlation
has been reported to be associated with renal relapse between lumenal macrophages and crescents at Bx1
[40], only one study to date has commented on their prog- (0.57***). Likewise, Oda et al found a strong correlation
nostic significance in SLE renal biopsies. Magil et al between crescents and intratubular macrophages [44].
found that the presence of glomerular macrophages, as However, crescents do not provide the entire explana-
recognized by nonspecific esterase staining, seemed to tion, because even at Bx1 there are cases with lumenal
confer a protective effect on survival from renal insuffi- macrophages but without crescents, and vice versa, and
ciency [15]. Our results at Bx1 are similar to theirs, al- at Bx2, there is no significant correlation between the
though not reaching significance. However, our interpre- two (R 5 0.08). Barie´ty et al have shown convincingly
tation is different, in that we also found similar slightly
that glomerular podocytes are capable of transdifferenti-better survivals for patients with karyorrhexis/fibrinoid
ation into macrophages in noncrescentic lesions such asnecrosis, glomerular PMNs, and cellular crescents at Bx1,
focal segmental glomerulosclerosis, and it seems proba-as opposed to those without. It would be hard to attribute
ble that this is the more general phenomenon, of whicha protective effect to crescents. Rather, these results
crescents are simply a special example [45, 46].seem to correspond to the old clinical observation that
Macrophages might also conceivably migrate into theoften it is the most floridly involved cases that respond
tubules from the interstitium, but the studies to give nobest to therapy [22]. At Bx2, in the treated patient, the
support to this notion date [45–47], and we saw only verypresence of glomerular monocytes had a frankly negative
occasional PGM11 cells with rounded contours in theeffect on renal survival, with survivals at 10 years of 35.5
epithelium consistent with this possibility. In contrast,versus 75.8% for those without (P 5 0.0371).
these studies do support the possibility that macrophagesMagil et al did not detail the interrelationships be-
may form by transdifferentiation of tubular epithelialtween hyaline deposits, crescents, and glomerular mono-
cells. First, in focal segmental glomerulosclerosis, we havecytes in their original study [15]. However, in a subsequent
observed tubular epithelial cells doubly marked for cyto-study [31], they found inverse correlations between glo-
keratin and PGM1 (unpublished observations). Second,merular monocytes and IgG deposits on IF (20.45) and
experimentally, tubular epithelial cells have been demon-hyaline deposits (20.35) by light microscopy. Our results
strated to transdifferentiate into fibroblasts through aaccord with theirs in that we found a correlation of 20.73
series of stages that are morphological similar, that is,(P 5 0.04) between PGM11 glomerular capillary macro-
initially basolateral then expanding to supranuclear re-phages and IgG at Bx1 before treatment, with similar
gions, to those we describe for PGM1 staining in tubularnegative correlations for C3 and C1q, but we further found
epithelium [48]. It will require double marker studies,that treatment totally eliminated these correlations at Bx2.
however, to confirm that this occurs in lupus nephritis.Most attention to macrophages outside the glomerulus
The relative contributions of glomerular and tubularhas focused specifically on the interstitium, where their
cells to the intratubular macrophage population remain tonumbers have been shown to correlate positively with
be elucidated, but present evidence favors a predominantlySCr and negatively with GFR in SLE [41] and in other
disease processes [42–44] and on their role in the pro- glomerular origin (unpublished observations) [45–47].
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The role of the tubular lumenal macrophages is not whose persistence at repeat biopsy presages a dim future
entirely clear. Although experimentally the lipids attached prognostically [14, 19].
to excreted albumin have a chemotactic effect on macro-
Conclusionsphages [48], this is not the entire explanation. The associ-
ation of macrophages with SCr is higher at both time The present Biopsy Index was demonstrated in an
points than with proteinuria, particularly at Bx2, where earlier article to show greater predictive power and bet-
the correlation with SCr is r 5 0.43, and that with protein- ter correlations with current clinical data than the stan-
uria is r 5 20.01. This suggests that tubular macrophages dard NIH Index [1]. However, at the first biopsy, even
reflect glomerular and tubular injury not directly related this index is not adequately predictive of subsequent
to proteinuria. Oda et al have found that the tubular behavior. The first biopsy should be considered basically
macrophages often adhere to tubular epithelium, via in- as diagnostic and not, except in cases with far advanced
tercellular adhesion molecule-1 (ICAM-1) [44]. Since lesions, prognostic.
these macrophages have direct antibody-dependent and Systematic biopsy at six months has more predictive
-independent cytotoxity in other settings, it seems likely power by far, in that it provides a measure of the response
that they are involved in direct tubular damage here as to therapy. It is better, in fact, than clinical data alone.
well. Consistent with this view is the observation that at A dichotomy between an active biopsy and a quiescent
Bx1 there is an excellent correlation between the pres- clinical picture was quite common in our experience.
ence of tubular macrophages and tubular epithelial le- More than half of the patients who ultimately progressed
sions (0.57****). Regardless of the mechanisms involved, to CRX2 had SCr of ,100 mmol/L, proteinuria , 1.0 g/
their predictive ability is impressive. 24 h, and/or hematuria ,5000 rbc/mL at the time of the
The aim of the original study was to develop a morpho- second biopsy. A future communication, dealing pre-
logic index that could be applied to routine archival dominantly with the clinical aspects of this study, will
histologic material. The immunohistochemical staining demonstrate formally the significant added value of sys-
of a subset of biopsies for the macrophage marker PGM1 tematic second biopsy over clinical data alone (manu-
was designed to validate the archival variables. There script in preparation). For the present, it can be said
was a good correlation between PGM1-labeled cells and that we feel that a systematic second-look biopsy is an
simple identification of macrophages on routine stains. important adjunct in the treatment of lupus nephritis.
However, as was anticipated, the latter was inexact and The Biopsy Index offers a valuable tool in research
underestimated their true numbers. The correlations endeavors, but would frankly be somewhat unwieldy to
with SCr, proteinuria, and renal insufficiency were even use on a routine basis. However, the insights it provides
better using PGM1 than with the identification of macro-
into the importance of persistence of immune depositsphages on routine stains. We feel that the addition of
and/or significant inflammation at repeat biopsy havestains for macrophage markers to the standard panel of
immediate practical value in daily practice, on the basisstains in lupus nephritis will add considerably to our
of simple comparison of biopsies without the necessity ofability to interpret the lesions seen, particularly in view
formal quantitation. If the pathologist recognizes theseof the prognostic significance of tubular and glomerular
features, the clinician can be alerted that despite normalmacrophages.
or near normal clinical and laboratory data, the patient
is at risk of progression to renal failure.Membranoproliferative lesions
To our knowledge, no other series has reported an
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